Inhibition of prolactin and aldosterone secretion by the dopamine derivative ibopamine. 
In 7 patients with congestive heart failure acute oral administration of ibopamine, a new dopamine derivative, induced a significant decrease in serum prolactin and aldosterone without affecting serum growth hormone or cortisol.  The Metoclopramide-induced secretion of prolactin and aldosterone was blunted in 6 patients pretreated with 200 mg ibopamine.  The data are consistent with a dopaminergic effect of ibopamine due to a peripheral action, probably on D-2 receptors.